A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
This clinical trial assessed the safety and efficacy of Odanacatib in reducing fracture risk among postmenopausal women with osteoporosis. The study involved a total of 16,071 participants, with a randomized, double-blind, placebo-controlled design over a duration of up to 10 years, including extensions.
Indication: Postmenopausal Osteoporosis
Modality: small molecule
Target: Odanacatib (MK-0822)
Sponsor: Merck Sharp & Dohme LLC
Source URL: ClinicalTrials.gov
Source updated: Jun 11, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Odanacatib (MK-0822)
View original source fields
Condition raw: Postmenopausal Osteoporosis
Condition normalized: Postmenopausal Osteoporosis
Modality raw: Postmenopausal Osteoporosis
Modality normalized: small molecule
Target raw: Odanacatib (MK-0822)
Target normalized: Odanacatib (MK-0822)